Benjamin F. Edwards & Company Inc. Boosts Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

Benjamin F. Edwards & Company Inc. increased its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 10,124.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,785 shares of the company’s stock after acquiring an additional 44,347 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in 10x Genomics were worth $871,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its stake in shares of 10x Genomics by 113.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock worth $26,000 after acquiring an additional 371 shares during the last quarter. Covestor Ltd raised its holdings in 10x Genomics by 501.7% in the 1st quarter. Covestor Ltd now owns 1,047 shares of the company’s stock valued at $39,000 after acquiring an additional 873 shares during the last quarter. Headlands Technologies LLC purchased a new position in 10x Genomics in the 1st quarter worth approximately $71,000. First Horizon Advisors Inc. boosted its holdings in shares of 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock worth $37,000 after purchasing an additional 808 shares during the last quarter. Finally, VitalStone Financial LLC boosted its stake in 10x Genomics by 59,900.0% during the fourth quarter. VitalStone Financial LLC now owns 3,600 shares of the company’s stock worth $201,000 after buying an additional 3,594 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Stock Down 2.1 %

Shares of 10x Genomics stock opened at $22.21 on Tuesday. 10x Genomics, Inc. has a 52-week low of $15.28 and a 52-week high of $57.90. The company has a market capitalization of $2.65 billion, a P/E ratio of -9.96 and a beta of 1.85. The company has a 50 day moving average of $21.01 and a 200 day moving average of $25.11.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.15. The business had revenue of $153.10 million during the quarter, compared to analysts’ expectations of $150.90 million. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.23%. As a group, research analysts anticipate that 10x Genomics, Inc. will post -1.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TXG. Wolfe Research reiterated a “peer perform” rating on shares of 10x Genomics in a report on Thursday, June 27th. Jefferies Financial Group raised shares of 10x Genomics from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Monday, July 22nd. The Goldman Sachs Group dropped their price target on shares of 10x Genomics from $26.00 to $16.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. Bank of America lowered their price objective on shares of 10x Genomics from $36.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, July 18th. Finally, JPMorgan Chase & Co. cut 10x Genomics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $40.00 to $20.00 in a research note on Thursday, July 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.60.

Insider Transactions at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 6,749 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $152,054.97. Following the transaction, the chief executive officer now directly owns 882,467 shares in the company, valued at $19,881,981.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Serge Saxonov sold 6,749 shares of 10x Genomics stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $152,054.97. Following the sale, the chief executive officer now owns 882,467 shares in the company, valued at $19,881,981.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Justin J. Mcanear sold 2,961 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $66,711.33. Following the completion of the sale, the chief financial officer now directly owns 143,242 shares of the company’s stock, valued at $3,227,242.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,061 shares of company stock valued at $316,794. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.